Afatinib Dimaleate 40 mg Tablets are an oral, irreversible ErbB family blocker indicated for the treatment of adult patients with locally advanced or metastatic EGFR‑mutation positive non‑small cell lung cancer (NSCLC).
Afatinib inhibits the activity of EGFR, HER2, HER4 and other kinases, blocking tumor cell proliferation and survival signaling pathways, thereby suppressing tumor growth and progression.
Composition
Each film‑coated tablet contains:
Afatinib dimaleate equivalent to Afatinib 40 mg
Indications
First‑line treatment of adult patients with locally advanced or metastatic non‑small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)‑activating mutations.
Key Features
Potent and irreversible ErbB family tyrosine kinase inhibitor
Targeted action against EGFR‑mutant tumors
Oral administration, convenient dosing
Stable formulation with consistent bioavailability
Strict impurity control and quality stability
Produced in strict compliance with GMP standards
Full technical and registration dossiers available for global marketing
Storage
Store in a cool, dry place, protected from light and moisture.
Keep out of reach of children.
Precautions
For prescription use only. Administer under supervision of a qualified oncologist.
